Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Awards and Per Share Information

v3.4.0.3
Stock-Based Awards and Per Share Information
3 Months Ended
Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-Based Awards and Per Share Information

NOTE 3—STOCK-BASED AWARDS AND PER SHARE INFORMATION

Stock-Based Compensation

The Company currently has one stock-based compensation plan, the 2002 Stock Incentive Plan (as amended effective as of May 26, 2004, November 15, 2005, May 16, 2007, May 5, 2011, June 6, 2013, October 30, 2014, and April 27, 2015) (the “2002 Plan”), which will expire on May 5, 2019. Persons eligible to receive awards under the 2002 Plan include officers, employees, and directors of the Company, as well as consultants. As of March 31, 2016, a total of 11,550,000 shares have been authorized for issuance under the 2002 Plan, of which 3,098,000 shares of BIOLASE common stock have been issued pursuant to options that were exercised and restricted stock units (“RSUs”) that were settled in common stock, 5,134,000 shares of BIOLASE common stock have been reserved for outstanding options and unvested RSUs, and 3,318,000 shares of BIOLASE common stock remain available for future grants.

For the three months ended March 31, 2016 and 2015, the Company recognized stock-based compensation cost of $834,000 and $700,000, respectively, based on the grant-date fair value. The net impact to earnings for the three months ended March 31, 2016 and 2015 was $(0.01), and $(0.01) per basic and diluted share, respectively. At March 31, 2016, the Company had approximately $4.3 million of total unrecognized compensation cost, net of estimated forfeitures, related to unvested share-based compensation arrangements. The Company expects that cost to be recognized over a weighted-average period of 2.8 years.  

The following table summarizes the income statement classification of compensation expense associated with share-based payments (in thousands):

 

Three Months Ended

 

 

March 31,

 

 

2016

 

 

2015

 

Cost of revenue

$

70

 

 

$

76

 

Sales and marketing

 

134

 

 

 

293

 

General and administrative

 

551

 

 

 

236

 

Engineering and development

 

79

 

 

 

95

 

 

$

834

 

 

$

700

 

 

 

The stock option fair values, under the 2002 Plan, were estimated using the Black-Scholes option-pricing model with the following assumptions:

 

Three Months Ended

 

 

March 31,

 

 

2016

 

 

2015

 

Expected term

6.3 years

 

 

7.2 years

 

Volatility

88.30%

 

 

89.90%

 

Annual dividend per share

$

 

 

$

 

Risk-free interest rate

1.42%

 

 

1.78%

 

 

A summary of option activity under the 2002 Plan for the three months ended March 31, 2016 is as follows:

 

 

 

 

 

 

 

 

 

 

Weighted Average

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

Remaining

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Contractual

 

 

Intrinsic

 

 

Shares

 

 

Exercise Price

 

 

Term (Years)

 

 

Value(1)

 

Options outstanding, December 31, 2015

 

4,493,000

 

 

$

2.72

 

 

 

6.59

 

 

$

422

 

Granted at fair market value

 

295,000

 

 

$

0.86

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

$

 

 

 

 

 

 

 

 

 

Forfeited, cancelled, or expired

 

(283,000

)

 

$

2.87

 

 

 

 

 

 

 

 

 

Options outstanding at March 31, 2016

 

4,505,000

 

 

$

2.59

 

 

 

6.81

 

 

$

169,000

 

Options exercisable at March 31, 2016

 

2,932,000

 

 

$

2.89

 

 

 

5.92

 

 

$

38,000

 

Vested options expired during the quarter

   ended March 31, 2016

 

48,000

 

 

$

2.38

 

 

 

 

 

 

 

 

 

 

(1) The intrinsic value calculation does not include negative values. This can occur when the fair market value on the reporting date is less than the exercise price of the grant.

Cash proceeds, along with fair value disclosures related to grants, exercises, and vested options under the 2002 Plan are as follows for the three months ended March 31 (in thousands, except per share amounts): 

 

Three Months Ended

 

 

March 31,

 

 

2016

 

 

2015

 

Proceeds from stock options exercised

$

 

 

$

44

 

Tax benefit related to stock options

   exercised (1)

N/A

 

 

N/A

 

Intrinsic value of stock options exercised (2)

$

 

 

$

52

 

Weighted-average fair value of options granted

   during period

$

0.67

 

 

$

1.88

 

Total fair value of shares vested during

   the period

$

708

 

 

$

293

 

(1) Excess tax benefits received related to stock option exercises are presented as financing cash inflows. The Company currently does not receive a tax benefit related to the exercise of stock options due to the Company’s net operating losses.

(2) The intrinsic value of stock options exercised is the amount by which the market price of the stock on the date of exercise exceeded the market price of the stock on the date of grant.

Effective February 26, 2016 in connection with the Company’s new 2016 compensation plan, the Compensation Committee of the Board of Directors (the “Board”), awarded to certain employees and consultants of the Company a total of 295,000 non-qualified stock options to purchase shares of BIOLASE common stock.  These awards were issued at $0.86 per share, the closing market price of the BIOLASE common stock on the grant date, and expire 10 years from the grant date.  Vesting periods for options are as follows: (i) 185,000 options, awarded to existing employees, vest ratably over a 48 month period, commencing one month from the grant date, and (ii) 110,000 options, awarded to new 2016 employees, vest 25% on the one-year anniversary of the grant date and the remainder ratably over the 36-month period, commencing 13 months after of the grant date.

Restricted Stock Units

In accordance with the 2002 Plan, the Company approved restricted stock units (“RSUs”) to acquire shares of BIOLASE common stock as approved by the Board.  Effective February 26, 2016, the Compensation Committee of the Board issued the following awards:

Under with the 2015 compensation plan, 388,500 RSUs were awarded to certain employees and consultants of the Company.  These awards were valued at $0.86 per share, the closing market price of BIOLASE common stock on the grant date, and will fully vest on July 1, 2016.

Under with the new 2016 compensation plan, 140,000 RSUs were awarded to certain employees and consultants of the Company.  These awards were valued at $0.86 per share, the closing market price of BIOLASE common stock on the grant date, and vest 25% on each of the first, second, third, and fourth anniversaries of the grant date.

In connection with the President and Chief Executive Officer’s employment agreement, the maximum performance bonus was awarded, consisting of (i) $100,000 paid in cash during the three months ended March 31, 2016, and (ii) 59,523 RSUs, valued at $0.86 per share, the closing market price of BIOLASE common stock on the grant date.  Half of these RSUs will vest on March 30, 2016 and half of these RSUs will vest on February 18, 2017.  

Effective March 10, 2016, under with the 2015 compensation plan, the Compensation Committee of the Board approved the grant of 70,000 RSUs to the Company’s Chief Financial Officer.  These awards were valued at $1.23 per share, the closing market price of BIOLASE common stock on the grant date, and will fully vest on July 1, 2016.

 

A summary of option activity under the 2002 Plan for the three months ended March 31, 2016 is as follows:

 

 

 

 

 

Weighted

 

 

 

 

 

 

Average Grant

 

 

Shares

 

 

Date Fair Value

 

Nonvested restricted stock units at December 31, 2015

 

870,000

 

 

$

1.64

 

Granted

 

658,000

 

 

$

0.90

 

Vested

 

(30,000

)

 

$

0.86

 

Forfeited or cancelled

 

 

 

$

 

Nonvested restricted stock units at March 31, 2016

 

1,498,000

 

 

$

0.90

 

 

 

Warrants

The Company issues warrants to acquire shares of BIOLASE common stock as approved by the Board.

A summary of warrant activity for the three months ended March 31, 2016 is as follows:  

Warrants Outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Average

 

 

 

Shares

 

 

Exercise Price

 

 

Warrants outstanding, December 31, 2015

 

10,094,000

 

 

$

4.18

 

 

Granted

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

Forfeited, cancelled, or expired

 

 

 

 

 

 

 

Warrants outstanding at March 31, 2016

 

10,094,000

 

 

$

4.18

 

 

Warrants exercisable at March 31, 2016

 

9,959,000

 

 

$

4.18

 

 

Vested warrants expired during the quarter

   ended March 31, 2016

 

 

 

N/A

 

 

 

No warrants were exercised during the three months ended March 31, 2016.

Net Loss Per Share – Basic and Diluted

Basic net income (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of BIOLASE common stock outstanding for the period. In computing diluted net income (loss) per share, the weighted average number of shares outstanding is adjusted to reflect the effect of potentially dilutive securities.

Outstanding stock options and warrants to purchase approximately 15,228,000 and 15,563,000 shares were not included in the calculation of diluted loss per share for the three months ended March 31, 2016 and 2015, respectively, as their effect would have been anti-dilutive.